- Home
- DIBS vs CRBP Comparison
DIBS vs CRBP Comparison
Compare DIBS & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DIBS | CRBP |
|---|---|---|
| Founded | 2000 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.5M | 184.4M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | DIBS | CRBP |
|---|---|---|
| Price | $4.23 | $8.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.00 | ★ $45.50 |
| AVG Volume (30 Days) | 284.9K | ★ 657.9K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.45 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,620,000.00 | $4,822,272.00 |
| Revenue This Year | $3.12 | N/A |
| Revenue Next Year | $1.72 | $116.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.54 | ★ 97.62 |
| 52 Week Low | $2.50 | $6.73 |
| 52 Week High | $6.62 | $20.56 |
Technical Indicators
Market Signals| Indicator | DIBS | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 35.09 | 41.33 |
| Support Level | $3.55 | $7.72 |
| Resistance Level | $4.83 | $8.87 |
| Average True Range (ATR) | 0.20 | 0.91 |
| MACD | 0.01 | -0.29 |
| Stochastic Oscillator | 10.65 | 17.19 |
Price Performance
Historical ComparisonAbout DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company has a single reportable and operating segment that contains one reporting unit, which consists of the company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.